Introduction
Regulation of cellular growth and development by the insulin-like growth factors (IGFs) is well accepted and interventions that block the IGF axis as such are currently in development for cancer therapy (Jones et al., 2005) . In addition, various components of this axis are modulated by dietary and pharmacological cancer interventions (Voskuil et al., 2005) .
Insulin-like growth factor-binding protein-3 (IGFBP-3), one of six members of the IGFBP family that noncovalently bind to IGFs with high affinity, is the most abundant in human serum (for a review see Firth and Baxter, 2002) . IGFBP-3 is a multifunctional protein that transports and stabilizes IGFs in circulation; modulates IGF bioactivity; inhibits the growth of cancer cells; and induces apoptosis of cancer cells. The effects of IGFBP-3 on cell growth and apoptosis involve both sequestering IGFs from their receptors and IGF-independent mechanisms that include: binding to retinoid X receptor (RXR) and modulation of nuclear signalling followed by nucleomitochondrial translocation of RXR/Nur77 and induction of rapid apoptosis ; binding to membrane receptors (Huang et al., 2003) ; and antagonism of the recently described survival factor, humanin (Ikonen et al., 2003) . We have recently reported the initial description of successful therapeutic use of IGFBP-3 as a cancer therapy in vivo, and demonstrated that combination treatment of IGFBP-3 and RXR ligand had a synergistic effect on apoptosis induction leading to substantial inhibition of prostate cancer xenograft growth .
We hypothesized that apart from apoptosis induction, IGFBP-3 might have direct effects on angiogenesis because: (1) IGFBP-3 contains a highly basic heparinbinding area, and specifically binds to vascular endothelial cell monolayers (Booth et al., 1996) in a manner that may affect vascular angiogenesis; (2) IGFBP-3 inhibits vascular endothelial growth factor (VEGF)-mediated survival of human umbilical vein endothelial cells (HUVEC) in an IGF-independent mechanism (Zadeh and Binoux, 1997; Franklin et al., 2003) and may also affect angiogenesis in vivo; (3) IGFBP-3 is transcriptionally upregulated during hypoxia, a potent stimulator of angiogenesis (Diaz-Gonzalez et al., 2005) in endothelial cells (Koong et al., 2000) ; and (4) IGFBP-3 mRNA is predominantly expressed in the vascular endothelial cells of human (Fraser et al., 2000) , rat (Erickson et al., 1993) , and bovine corpus lutea (Brown and Braden, 2001) , which suggest a possible involvement in angiogenesis regulation, perhaps as part of a feedback mechanism. Other reports also indicate that IGFBP-3 mRNA is more abundantly expressed in hypoxia-associated inflammatory angiogenesis (Tucci et al., 1998; Lee et al., 1999) and tumor endothelial cells (Schmid et al., 2003) . Importantly, a recent publication identifies IGFBP-3 as a farnesyl transferase inhibitorinduced negative regulator of angiogenesis in head and neck squamous cell carcinoma (Oh et al., 2006) .
Here, we report that IGFBP-3 has direct, IGFindependent inhibitory effects on angiogenesis. Solid tumors require a supply of blood vessels to survive, grow and metastasize (Folkman, 2004) and treatments that address these issues can be more effective than nonspecific chemotherapies. Our results reveal a unique mechanism by which IGFBP-3 exerts its tumor suppressive effects and supports further investigation into the clinical translation of IGFBP-3 as a neoadjuvant in prostate cancer therapy.
Results
IGFBP-3 inhibits the growth of 22RV-1 prostate cancer xenografts in vivo To examine the effects of IGFBP-3 as a single therapy on inhibiting prostate cancer tumor cell growth in vivo, male severe-combined immunodeficiency (SCID) mice with 22RV-1 prostate cancer xenografts were given daily injections of saline, or IGFBP-3 (30 mg/kg/day intraperitoneally (i.p.)) for 16 days. Treatment with IGFBP-3 resulted in significant tumor size inhibition (40% growth inhibition, Po0.005; n ¼ 10) relative to control animals ( Figure 1a) . A greater effect (50% inhibition) was seen for IGFBP-3 therapy on tumor weight (Figure 1b ). These studies show that treatment of IGFBP-3 as a single therapy inhibits the growth of 22RV1 prostate cancer xenografts.
Induction of tumor apoptosis by IGFBP-3
Inhibition of xenograft growth by IGFBP-3 and RXR ligand is associated with an increase in apoptosis and activated Caspase-3 . The effect of IGFBP-3 single therapy on apoptosis in this xenograft model was examined by light microscopic terminal nucleotidyl transferase-mediated nick end labeling (TUNEL) assay. Representative photographs are shown in Figure 2a . As shown in Figure 2b , quantification of TUNEL-positive cells was increased sevenfold in the IGFBP-3 treatment group over saline-treated tumors. We next assessed whether this effect of IGFBP-3 is associated with an in vivo activation of Caspase-3. Microscopic examination of tumor sections stained for Caspase-3 clearly showed an increased detection of Caspase-3 in the IGFBP-3 therapy group as compared with the control group (Figure 2c ). Quantification of Caspase-3-positive staining was increased sevenfold in IGFBP-3 treatment group over saline-treated tumors (Figure 2d ). To further evaluate if regulation of cellular proliferation is also involved in the actions of IGFBP-3 on prostate cancer xenografts, we stained the tumors with the proliferation marker proliferating cell nuclear antigen (PCNA), and as shown in Figure 2e , observed no difference between IGFBP-3 and saline treatment (quantified in Figure 2f ), suggesting that IGFBP-3-mediated inhibition of tumor growth does not involve regulation of cell proliferation. Negative controls, in which PCNA antibodies were omitted, did not show any positive staining (data not shown). This is in agreement with our previous observation utilizing a lower dose of IGFBP-3 .
IGFBP-3 decreases vessel formation in vivo
Microvessel density, a measurement used for quantifying intratumoral angiogenesis activity, has been suggested as a valuable prognostic marker in prostate carcinoma (Weidner et al., 1993) . To investigate if IGFBP-3 had any effect on intratumoral angiogenesis, we carried out immunohistochemical staining using an antibody against CD31, an endothelial cell-specific antigen, to evaluate the antiangiogenic effect of IGFBP-3 on 22RV1 tumor xenografts. As shown in Figure 3 , a twofold increased number of CD31-positive microvessels and endothelial cells were found in the control group compared to the IGFBP-3-treated group. Our results indicate that IGFBP-3 is able to suppress prostate cancer angiogenesis through inhibiting microvessel formation.
IGFBP-3 inhibits both IGF-and VEGF-induced vascular formation VEGF is one of the most potent angiogenic factors affecting endothelial proliferation, motility and vascular IGFBP-3 inhibits angiogenesis B Liu et al permeability. VEGF binds with high affinity to the tyrosine kinase receptors Flt-1 (VEGFR-1) and Flk-1/ KDR (VEGFR-2) expressed by endothelial cells (Ferrara, 2001) . VEGF expression by prostate cancer specimens is far greater than that by stromal cells of the normal prostate. These observations suggest that VEGF plays a role on tumor cell activation (autocrine regulation), in addition to paracrine actions, whereby it regulates endothelial cell (EC) functions and subsequent neovascular development (Jackson et al., 1997) . We further investigated the effect of IGFBP-3 on VEGFregulated vascular formation, using an established in vitro model of human endothelial cellular vessel formation in matrigel (Iwatsuki et al., 2005) . IGFBP-3 alone has no effect on vascular formation in this assay; however, VEGF stimulated substantial new vascular complex formation. Importantly, VEGF-induced vessel formation was completely inhibited by IGFBP-3 cotreatment ( Figure 4 ). To further explore if effect of IGFBP-3 on VEGFregulated vascular formation and to examine its effects on IGF-regulated vascular formation and to determine if this is an IGF-independent action, human endothelial cells on matrigel were treated individually with IGF-1, IGFBP-3, Long R3-IGF-1 (an IGF-1 analog which does not bind IGFBP-3) or their combination (Figure 4 ). IGF-1 stimulated vascular formation consistent with its described angiogenic effect (Hanahan and Folkman, 1996) . IGFBP-3 blocked the angiogenic effect of IGF-1. Long R3-IGF-1, which does not bind IGFBP-3 also stimulates vascular formation and is partially blocked by IGFBP-3, indicating that IGFBP-3 interferes with 
IGFBP-3 inhibits in vivo angiogenesis
To investigate the antiangiogenic activity in an in vivo setting, rhIGFBP-3 was tested on chicken embryo chick allantoic membrane (CAM) and murine matrigel plug angiogenesis assays. Compared to phosphate-buffered saline (PBS) control, IGFBP-3 at doses of 2.5 and 10 mg/ disk completely inhibited the growth of new vascular vessels in all six tested chick embryos, which was measured by the formation of avascular zones ( Figure 5 ). No inflammation was observed in these studies. Basic fibroblast growth factor (bFGF)-induced angiogenesis has been considered as a model of tumor-derived neovacularization (Klauber et al., 1997) . Figure 6 shows that the bFGF plugs were bright red and contained a large numbers of micro-blood vessels, which penetrated into the solidified martrigel and spread widely. There were no blood vessels in the PBS plugs (data not shown). However, the numbers of micro-blood vessels decreased in the plugs with both bFGF and different doses of rhIGFBP-3 in a dose-dependent manner. Quantification by image analysis showed that bFGF-induced neovascularizations were inhibited by 17 and 75% at the doses of 2.5 and 5 mg/ml rhIGFBP-3, respectively. Addition of 10 mg/ml of IGFBP-3 to FGF-2 was not significantly different from the 5 mg/ml dose.
Overexpression/ectopic expression of human IGFBP-3 inhibits vascular patterning in Zebrafish embryos in an IGF-independent manner To assess the role of IGFBP-3 in blood vessel patterning in vivo, we overexpressed/ectopic expressed human Figure 5 Antiangiogenic effects of rhIGFBP-3 on the CAM assay. Methylcellulose disks containing PBS, 2.5 and 10 mg of IGFBP-3 were implanted on CAMs of 6-day-old chick embryos. After 3-4 days, the formation of avascular zone was examined under a stereoscope. Each treatment was repeated in six chick CAMs with similar results.
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IGFBP-3 via injection of the corresponding mRNA into the cytoplasm of one-cell stage flk1:green fluorescent protein (GFP) transgenic Zebrafish embryos. flk1:GFP represents a stable integration of a GFP reporter gene driven by the promoter of VEGF receptor-2 (flk1) and it utilized in the rapid, high-throughput screening of antiangiogenesis drug screening (Cross et al., 2003) . As the vascular endothelial cells are labeled with green fluorescence, the blood vessels can be easily visualized in live embryos in this transgenic fish line. As shown in Figure 7 , introduction of IGFBP-3 (300 pg of mRNA) resulted in defects of vascular patterning in the trunk and tail regions (Figure 7 ) in 36 h.p.f. (hours post fertilization) embryos. Intersegmental vasculogenesis is severely affected. Vessels are lacking and the remaining vessels are abnormally positioned. In addition, regional somites are compressed compared to control fish. To test whether the observed effect is dependent on the function of IGFBP-3 in IGF-sequestration, mRNA from a mutant form of IGFBP-3 which is defective in IGF binding was injected into flk1:GFP embryos in parallel with wild-type form. The phenotype in embryos injected with the mutant form is essentially indistinguishable from that with wild-type IGFBP-3, indicating that the effect of IGFBP-3 on vasculogenesis is independent of IGF sequestration. These apparently dorsalized embryos resemble previously characterized Zebrafish mutants such as the notochord mutant ntl, which shows defects in notochord differentiation (Odenthal et al., 1996) as well as the dominant-negative IGF-1R overexpression mutant (Eivers et al., 2004) .
Discussion
In prostate cancer, as in other cancers, tumor-associated angiogenesis is a crucial step in the process of tumor growth, invasion and metastasis (van Moorselaar and Voest, 2002) . Previous studies on prostate cancers have demonstrated a correlation between microvessel density, pathological stage and Gleason score (Arakawa et al., 1997; Bettencourt et al., 1998; Bono et al., 2002) . Therefore, inhibiting vessel formation offers hope to reduce the morbidity and mortality from prostate cancer, and solid tumor cancers in general (Folkman, 1971) . Two reports have shown that IGFBP-3 inhibited the growth of bovine aortic endothelial cells (Delafontaine et al., 1996) and the IGF-/VEGF-induced proliferation of HUVEC (Franklin et al., 2003) . In addition, IGFBP-3 is inhibitory for both proliferation and in vitro angiogenesis of the mouse endothelial progenitor cell line AEL-R1/LRT-Runx1 in a manner independent from growth inhibitory effects of IGFBP-3 (Iwatsuki et al., 2005) . This was shown to be specific to IGFBP-3 as IGFBP-6 was not inhibitory for in vitro angiogenesis of AEL-R1/LRT-Runx1 cells, even at a higher concentration.
It has been reported that VEGF and transforming growth factor 1 downregulate the expression 
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of IGFBP-3 in aortic endothelial cells (Erondu et al., 1996; Dahlfors and Arnqvist, 2000) , whereas IGF, tumor necrosis factor-a and interleukin-1 upregulate it in endothelial cells or articular chondrocytes (Olney et al., 1995; Erondu et al., 1996) . Thus, IGFBP-3 may be a downstream effector for many growth regulatory cytokines and its transcription must be regulated differently depending on the cell type. Indeed, knockdown of IGFBP-3 expression by RNA interference or neutralizing antibodies blocked the antiangiogenic effect of the farnesyl transferase inhibitor SCH66336 in head and neck squamous cell carcinoma (Oh et al., 2006) . IGFBP-3 is known to be overexpressed during the angiogenic phase of the corpus luteum in rats, primates and humans (Erickson et al., 1993; Fraser et al., 1998 Fraser et al., , 2000 . Other reports also indicate that IGFBP-3 mRNA is more abundantly expressed in hypoxia-associated inflammatory angiogenesis (Tucci et al., 1998; Lee et al., 1999) and tumor endothelial cells (Schmid et al., 2003) . Indeed, hypoxia is the major pathophysiological condition regulating angiogenesis, and increased angiogenesis in response to hypoxia is part of an adaptive response aimed at achieving increased delivery of oxygen and nutrients to tissues (Acker and Plate, 2003) . IGFBP-3 is induced by hypoxia (Grimberg et al., 2005) and may be involved in the normalization of tumor vasculature, modulating the abnormal structure and function of tumor vasculature (Jain, 2005) . Chan et al. (1998) demonstrated that plasma level of IGFBP-3 was a predictor of advanced-stage prostate cancer (relative risk ¼ 0.2, 95% confidence interval 0.1-0.6 for the highest versus the lowest quartiles of IGFBP-3). Lee et al. (2002) has reported that the overexpression of rhIGFBP-3 by an adenoviral vector, Ad5CMV, inhibited the growth of non-small-cell lung cancer cells in tumor xenografts. Singh et al. (2004b) showed that the antitumor effects of both grape seed extract and inositol hexaphosphate (Singh et al., 2004a) were associated with a concomitant rise in serum IGFBP-3 and importantly, suppression of angiogenesis as measured by tumor vessel immunohistochemistry and serum VEGF levels. Silibinin, an antioxidant flavonoid, also inhibits prostate cancer xenograft growth and was associated with a decrease in tumor VEGF staining as well as increased intracellular IGFBP-3 staining (Singh et al., 2003) in mice.
Evidence for IGF-independent actions of IGFBP-3 include: (1) effects on cells that lack a functional type 1 IGF receptor (Valentinis et al., 1995) ; (2) IGFBP-3 binds other protein partners (receptors) that are not associated with IGFs (Liu et al., 2000; Huang et al., 2003; Ikonen et al., 2003) ; and as supported in the current study, (3) IGF analogs that do not bind IGFBP-3 fail to block IGFBP action (Franklin et al., 2003) ; and (4) IGFBP-3 mutants that do not bind IGFs maintain biologic actions (Chan et al., 2005) . In the present study, we further support this concept by demonstrating antagonism of VEGF action and reporting data utilizing a mutant form of IGFBP-3 with greatly reduced IGF binding in Zebrafish.
In summary, these data provide evidence for the first time that rhIGFBP-3 has direct inhibitory effects on angiogenesis. As invasion and angiogenesis are important determinants of tumor progression, this newly described function of IGFBP-3 could have important relevance to both the prediction of cancer progression as a biomarker and cancer therapy as a therapeutic target. Collectively, these results suggest that inhibition of human prostate cancer growth by IGFBP-3 is associated with its in vivo antiproliferative, proapoptotic and antiangiogenic efficacy and supports further research into the potential clinical use of IGFBP-3 or pharmacological inducers of IGFBP-3 as neoadjuvant approaches for patients with prostate cancer.
Materials and methods
Cell culture 22RV1 cells were from ATCC (Manassas, VA, USA) and maintained as directed. HUVEC and Microvascular Endothelial Cell Growth Medium Bullet Kit-2 (EGM-2-MV Bullet Kit) were purchased from Clonetics (San Diego, CA, USA) and maintained as directed. All cultures were incubated at 371C in a humidified atmosphere containing 5% CO 2 .
Tumor xenografts 22RV1 xenograft tumors were generated by injection of 1 Â 10 6 cells in 200 ml mixed at a 1:1 dilution with matrigel in the right flank of male SCID mice. Tumors were established for 2 weeks before the start of treatment. Ten SCID mice with 22RV1 tumors were treated daily with saline or IGFBP-3 (30 mg/kg/ day), given by daily i.p. injections for 16 days. The length and width of the mass located at the site of injection of the 22RV1 cells were measured with calipers and recorded once a week. The mice were killed at day 16. Tumors were harvested, weighed, fixed in formaldehyde and embedded in paraffin. Animal care was in accordance with current regulations and standards of the National Institutes of Health, as well as our institutional guidelines for animal care. All animal experiments were approved by the animal research committee of the institutional review board.
Tumor immunohistochemistry
Paraffin-embedded sections were prepared from 22RV1 tumors harvested on day 16. After deparaffinization of tissue section, apoptotic DNA fragments were labeled by terminal deoxynucleotidyl transferase, and detected by antidigoxigenin antibody conjugated to fluorescein (ApopTag fluorescein in situ apoptosis detection kit, Chemicon, Temecula, CA, USA). Cells were examined at Â 40 using an inverted fluorescence microscope (Axiovert 135M, Carl Zeiss, New York, NY, USA). Apoptotic staining was quantified by pixel histogram (Adobe Systems, Mountain View, CA, USA) and confirmed by manual counting (r ¼ 0.98) by counting the positive cells (brown-stained), as well as the total number of cells in 10 arbitrarily selected fields by an independent observer. Indirect immunohistochemistry was performed with Vectastain Elite ABC kit (Vector Labs, Burlingame, CA, USA) using 3,3 0 -diaminobenzidine as a chromogen and quantitated as per TUNEL assay above. Sections were incubated with mouse monoclonal antibodies against PCNA (Ab-1, 1:2500; Oncogene Science, Manhasset, NY, USA), CD31 (JC70A, 1:20; Dako Corp., Carpinteria, CA, USA), In vitro vascular formation matrigel assays HUVEC cells (1.5 Â 10 5 ) were resuspended in 1 ml of StemPro-34 SFM complete medium (Invitrogen, Carlsbad, CA, USA) with or without recombinant human IGFBP-3 or VEGF (Sigma, St Louis, MO, USA) and overlayed on a Biocoat matrigel basement membrane (BD Biosciences, San Jose, CA, USA) in a six-well plate. After a 12-14 h incubation at 371C, the number of polygonal areas formed by vascular tube-like structures was counted under a microscope for each well (Iwatsuki et al., 2005) .
Materials
Recombinant human IGFBP-3 and IGF-1 were obtained from INSMED Corp. (Glen Allen, VA, USA), aliquoted and stored at À801C. The activity of rhIGFBP-3 for both IGF-I-binding and -inhibitory effect on cell proliferation of human breast cancer MCF7 cells was confirmed by Western ligand blotting and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay as described previously (Pratt and Pollak, 1994) , respectively, before the experiments (data not shown). bFGF and the rabbit antiserum against human IGFBP-3 were purchased from Upstate Inc. (Lake Placid, NY, USA). Long R3-IGF-1 was obtained from Gropep (Adelaide, Australia). Matrigel (11.46 mg/ml) was from Becton Dickinson Labware (Bedford, MA, USA).
Chicken embryo chorioallantoic membrane assay Three-day-old fertilized white Leghorn eggs were cracked, and chicken embryos with intact yolks were carefully placed in 20 Â 100 mm plastic Petri dishes. After 6 days of incubation in 3% CO 2 at 371C, a disk of methylcellulose containing 10, 5 and 2.5 mg of rhIGFBP-3 dried on a nylon mesh (3 Â 3 mm) was implanted on the CAM of individual embryos. The nylon mesh disks were made by desiccation of 10 ml of 0.45% methylcellulose in water. After 3-4 days of incubation, embryos and CAMs were examined for the formation of new blood vessels in the field of the implanted disks by a dissecting microscope. Disks of methylcellulose containing PBS were used as negative controls (Cao et al., 1998) .
Murine matrigel plug angiogenesis assay Angiogenesis was assayed as the growth of blood vessels from subcutaneous tissue of mice into a solid gel of reconstituted basement membranes containing the test sample. Matrigel in liquid form at 41C was mixed with bFGF (1 mg) and with PBS, or 2.5, or 5 or 10 mg/ml rhIGFBP-3, and then injected into the abdominal subcutaneous tissue of six mice/group. At body temperature, the matrigel rapidly solidifies. Mice were killed 2 weeks later, and the matrigel plugs were exposed for photography (Bagheri-Yarmand et al., 1999) .
Zebrafish mRNA microinjection
Templates for transcription were prepared by linearizing plasmids pcDNA3IGFBP3 (wild-type IGFBP-3) and pcDNA1GGGBP-3 (non-IGF-binding GGG mutant of IGFBP-3 (Buckway et al., 2001) ) with SmaI. Capped mRNA was synthesized in vitro using the mMESSAGE mMACHINE Kit (Ambion, Austin, TX, USA). After purification as recommended by the manufacturer, RNA was dissolved in nuclease-free water at a concentration of approximately 500 ng/ml. The RNA was diluted to a final concentration of 100 ng/ml and injected into the cytoplasm of one-cell stage flk1:GFP Zebrafish embryos.
Fluorescence microscopy
Embryos were examined under a fluorescein isothiocyanate filter on a Zess microscopy (Zeiss Axioplan-2, Thornwood, NY, USA). Pictures represent an area of 500 Â 500 mm imaged with a Â 20/0.7 NA HC PlanApo lens. GFP was detected at a spectral range from 507 to 550 nm.
Statistical analysis
All in vitro experiments were repeated at least three times. Means7s.d. are shown. Statistical analyses were performed using analysis of variance tests using InStat (GraphPad, San Diego, CA, USA). Differences were considered statistically significant when *Po0.05 and when **Po0.005.
